Browsing by Author "Loirat, Delphine"
Now showing items 1-5 of 5
-
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Bardia, Aditya; Tolaney, Sara M; Punie, Kevin; Loirat, Delphine; Antunes de Melo Oliveira, Ana Mafalda; Kalinsky, K. (Elsevier, 2021-09) -
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
Loibl, Sibylle; Loirat, Delphine; Tolaney, Sara M; Punie, Kevin; Antunes de Melo Oliveira, Ana Mafalda; Rugo, Hope (Elsevier, 2023-01) -
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
Carey, Lisa; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Dieras, Veronique; Dalenc, Florence; Cortés Castan, Javier (Nature Research, 2022-06-09) -
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
Bardia, Aditya; Marmé, Frederik; Cortés Castan, Javier; Loirat, Delphine; Gómez Pardo, Patricia; Schmid, Peter; Rugo, Hope (American Society of Clinical Oncology, 2022-10-10) -
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
Tolaney, Sara M; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Hurvitz, Sara; Cortés Castan, Javier; Rugo, Hope (Breast Cancer Research Foundation, 2022-08-29)